1/29/2007

Genentech issued a letter to physicians warning its Lucentis drug for treating age-related macular degeneration may increase risk of stroke, particularly at high doses. The company called its cautionary letters to physicians a proactive step, but said the risks are in line with the drug's labeling.

Related Summaries